Skip to main content
| News

EsoCap impresses investors

25.11.2021

EsoCap, a biotech company based in Basel, has concluded a successful funding round. The funds from new and existing investors are to be used to drive forward a phase II clinical trial of a treatment for esophageal disorders.

EsoCap develops forms of treatment for diseases of the upper gastrointestinal tract, which also includes the esophagus. According to a press release, the Basel-based biotech company will now push forward with a phase II clinical trial on a treatment for eosinophilic esophagitis, a chronic inflammatory disorder of the esophagus. It is using fresh funds from a financing round initiated by the Canton of Basel-Stadt to do so.

The canton started a corresponding initiative to support companies during the coronavirus pandemic. EsoCap applied as a participant for this and was accepted. Both new and existing investors were involved in the subsequent funding round. Isabelle Racamier, CEO of EsoCap, comments in the press release: “We are proud to have the confidence of the Canton of Basel-Stadt and private investors.”

Medication to treat esophageal disorders only has a few seconds for its effect to act locally when moving from the mouth through the esophagus into the stomach. This is why EsoCap hopes to improve administration. The platform developed for this should not only help those with eosinophilic esophagitis but also other diseases such as Barrett’s esophagus or acid reflux. According to Racamier, there is a high need for suitable treatments in this area. EsoCap’s lead product candidate, ESO-101, has already received orphan drug status from the American regulatory authority, the Food and Drug Administration, meaning that it is a recognized treatment option for a rare disease.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Invest

How Moderna is growing in Switzerland

The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sandoz decides on Basel for headquarters

Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...

Read More
VectivBio sold for approximately 1 billion dollars
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio sold for approximately 1 billion dollars

The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

University of Basel and RocketVax present new Covid vaccine

Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest

Rami Swiss and Elbit Systems now manufacturing in Jura

The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Basel to become Europe’s Silicon Valley of biotech

Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....

Read More
1 2 3 63

Do you have a question? We'd like to hear from you.